Salarius Pharmaceuticals (Salarius Pharmaceuticals) Inventory Turnover : 0.00 (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Salarius Pharmaceuticals Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Salarius Pharmaceuticals's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil. Salarius Pharmaceuticals's Average Total Inventories for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Salarius Pharmaceuticals Inventory Turnover Historical Data

The historical data trend for Salarius Pharmaceuticals's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Salarius Pharmaceuticals Inventory Turnover Chart

Salarius Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventory Turnover

Get a 7-Day Free Trial

Salarius Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Inventory Turnover	Get a 7-Day Free Trial															-	-	-	-	-

Salarius Pharmaceuticals Inventory Turnover Calculation

Salarius Pharmaceuticals's Inventory Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Inventory Turnover (A: Dec. 2023 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (A: Dec. 2023 )	/ (	(Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Salarius Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

	Inventory Turnover (Q: Mar. 2024 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (Q: Mar. 2024 )	/ (	(Total Inventories (Q: Dec. 2023 )	+	Total Inventories (Q: Mar. 2024 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Salarius Pharmaceuticals (NAS:SLRX) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Salarius Pharmaceuticals's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Salarius Pharmaceuticals's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	0	/	0
	=

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Salarius Pharmaceuticals Inventory Turnover Related Terms

Thank you for viewing the detailed overview of Salarius Pharmaceuticals's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Salarius Pharmaceuticals (Salarius Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Salarius Pharmaceuticals Inc (NAS:SLRX) » Definitions » Inventory Turnover

Comparable Companies

Traded in Other Exchanges

FP1:Germany

Address

2450 Holcombe Boulevard, Suite X, Houston, TX, USA, 77021

Website

https://www.salariuspharma.com

Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The Company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

Executives

Tess Burleson	director	2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Jonathan I Lieber	director	C/O HISTOGENICS CORPORATION, 830 WINTER STREET #3, WALTHAM MA 02451
William K. Mcvicar	director	C/O INOTEK PHARMACEUTICALS CORPORATION, 131 HARTWELL AVENUE, SUITE 105, LEXINGTON MA 02421
Arnold C Hanish	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Mark J Rosenblum	officer: Exec VP Finance, Interim CFO	3990 SPRING VALLEY ROAD, APT. 1218, DALLAS TX 75244
David J. Arthur	director, officer: Chief Executive Officer	2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Scott Jordan	officer: Chief Financial Officer	2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Mccreedy Bruce J Jr.	director	2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Jonathan P Northrup	director	2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Pao-yu Chuang	officer: Controller	2450 HOLCOMBE BLVD., SUITE J-608, HOUSTON TX 77021
Paul Lammers	director	2408 TIMBERLOCH PLACE, B-7, THE WOODLANDS TX 77380
Boston Foundation, Inc.	10 percent owner	75 ARLINGTON STREET, BOSTON MA 02116
Christoph H Westphal	10 percent owner	C/O ALNYLAM PHARMACEUTICALS, INC, 300 THIRD STREET, CAMBRIDGE MA 02142
Longwood Fund Ii, L.p.	10 percent owner	800 BOYLSTON STREET, SUITE 1555, BOSTON MA 02199
Roger D Tung	director	99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421